IPP Bureau
USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
By IPP Bureau - November 16, 2024
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
By IPP Bureau - November 16, 2024
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM
By IPP Bureau - November 16, 2024
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu
By IPP Bureau - November 15, 2024
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr
By IPP Bureau - November 15, 2024
NABH integrates FOGSI’S maternal health standards across its certification programs
By IPP Bureau - November 15, 2024
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
By IPP Bureau - November 14, 2024
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024
By IPP Bureau - November 14, 2024
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
By IPP Bureau - November 14, 2024
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
By IPP Bureau - November 14, 2024
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Cupid Q2 FY25 income up 29.7%; PAT up 96.2%
By IPP Bureau - November 13, 2024
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
By IPP Bureau - November 13, 2024
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility
By IPP Bureau - November 13, 2024
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Divyesh Maru appointed CFO of Hester Biosciences
By IPP Bureau - November 13, 2024
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
